110025-28-0

Basic information

• Product Name: N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture)
• Synonyms: 4-[1-[4-[2-(methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol;4OHNDtam;E/Z Endoxifen;N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture);4-hydroxy-N-desmethyltamoxifen;4-[(E)-1-[4-(2-methylaminoethoxy)phenyl]-2-phenyl-but-1-enyl]phenol;4-[(Z)-1-[4-[2-(Methylamino)ethoxy]phenyl]-2-phenyl-1-butenyl]phenol;N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) see H938500
• CAS NO: 110025-28-0
• Molecular Formula: C₂₅H₂₇NO₂
• Molecular Weight: 373.493
• Product Categories: Intermediates & Fine Chemicals;Metabolites & Impurities;Pharmaceuticals;Aromatics
• Mol File: 110025-28-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 63-72°C
• Boiling Point: 519.3°Cat760mmHg
• Flash Point: 267.9°C
• Appearance: /
• Density: 1.099g/cm³
• Vapor Pressure: 2.1E-11mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform, Dichloromethane, DMSO, Methanol
• PKA: 9.38±0.15(Predicted)
• CAS DataBase Reference: N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture)(CAS DataBase Reference)
• NIST Chemistry Reference: N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture)(110025-28-0)
• EPA Substance Registry System: N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture)(110025-28-0)

Safety Data

• Hazardous Substances Data: 110025-28-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) is used as an active pharmaceutical ingredient for the development of anti-cancer drugs, specifically targeting estrogen receptor-positive breast cancer. Its potent ER binding property and ability to block estrogen-stimulated growth make it a valuable compound in the fight against breast cancer.
Used in Cancer Research:
In the field of cancer research, N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) serves as a crucial tool for studying the mechanisms of estrogen receptor-positive breast cancer and the development of novel therapeutic strategies. Its half-maximal inhibition of estrogen-responsive gene expression in ER-positive human breast cancer cell lines makes it an essential component in understanding the molecular pathways involved in cancer progression and resistance to treatment.
Used in Drug Development:
N-Desmethyl-4-hydroxy Tamoxifen (approx. 1:1 E/Z Mixture) is utilized in drug development for the creation of new pharmaceutical formulations and combination therapies. Its unique properties and potential synergistic effects with other anti-cancer agents make it a promising candidate for improving the efficacy and reducing the side effects of existing treatments for breast cancer.

InChI:InChI=1/C25H27NO2/c1-3-24(19-7-5-4-6-8-19)25(20-9-13-22(27)14-10-20)21-11-15-23(16-12-21)28-18-17-26-2/h4-16,26-27H,3,17-18H2,1-2H3/b25-24+

Upstream product

• 74-89-5 methylamine 
• 147323-02-2 E/Z-1-[4-(2-bromoethoxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbutene 
• 94972-95-9 4-hydroxy-4'-benzyloxybenzophenone 
• 185223-78-3 (E,Z)-1-[4-(benzyloxy)phenyl]-1-(4-hydroxyphenyl)-2-phenylbut-1-ene 
• 611-99-4 4,4'-Dihydroxybenzophenone 
• 79578-62-4 (4-(2-bromoethoxy)phenyl)(4-hydroxyphenyl)methanone 
• 850256-21-2 E/Z-1-[4-(2-bromoethoxy)phenyl]-1-(4-methoxyphenyl)-2-phenylbut-1-ene 
• 671791-56-3 1-(4-methoxymethoxyphenyl)-1-(4-methoxyphenyl)-2-phenylbutan-1-ol 
• 850256-19-8 E/Z-1-(4-hydroxyphenyl)-1-(4-methoxyphenyl)-2-phenylbutene 
• 115499-97-3 4-(methoxymethoxy)-4'-methoxybenzophenone 
• 61002-54-8 4-hydroxy-4'-methoxybenzophenone 
• 103-65-1 phenylpropane 

Downstream Products

• 671791-76-7 E/Z-N-[2-hydroxy-5-({2-[(2-{4-[1-(4-hydroxyphenyl)-2-phenylbut-1-enyl]phenoxy}ethyl)methylamino]ethoxyimino}methyl)benzamide]doxorubicin 
• 1189368-74-8 N-Boc-endoxifen 
• 1361381-82-9 C₄₄H₅₄N₄O₆ 
• 1361381-83-0 C₄₆H₅₈N₄O₆ 
• 1361381-84-1 C₄₈H₆₂N₄O₆ 
• 1372937-21-7 endoxifen ethyl formate 

Relevant articles and documents

Bioorthogonal release of anticancer drugs: Via gold-triggered 2-alkynylbenzamide cyclization

Metal-based uncaging of biomolecules has become an emerging approach for in vivo applications, which is largely due to the advantageous bioorthogonality of abiotic transition metals. Adding to the library of metal-cleavable protecting groups, this work introduces the 2-alkynylbenzamide (Ayba) moiety for the gold-triggered release of secondary amines under mild and physiological conditions. Studies were further performed to highlight some intrinsic benefits of the Ayba protecting group, which are (1) its amenable nature to derivatization for manipulating prodrug properties, and (2) its orthogonality with other commonly used transition metals like palladium and ruthenium. With a focus on highlighting its application for anticancer drug therapies, this study successfully shows that gold-triggered conversion of Ayba-protected prodrugs into bioactive anticancer drugs (i.e. doxorubicin, endoxifen) can proceed effectively in cell-based assays.

TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE

Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.

Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells

The anthracycline antitumor drug, doxorubicin (DOX), has long been used as a broad spectrum chemotherapeutic. The literature now documents the role of formaldehyde in the cytotoxic mechanism, and anthracycline-formaldehyde conjugates possess substantially